New wrinkle for HIV vaccine

Developing a vaccine for HIV may be harder than researchers thought, according to linkurl:a study;http://www.nature.com/nature/journal/vaop/ncurrent/full/nature07746.html published online in Nature. Just as the virus develops resistance to antiviral drugs, it also evolves to evade the human immune system on a population-wide level, the researchers report.Human Immunodeficiency Virus Image: NIAID Previous studies have examined the interaction of viral evolution with the human immune system in s

Written byAlla Katsnelson
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
Developing a vaccine for HIV may be harder than researchers thought, according to linkurl:a study;http://www.nature.com/nature/journal/vaop/ncurrent/full/nature07746.html published online in Nature. Just as the virus develops resistance to antiviral drugs, it also evolves to evade the human immune system on a population-wide level, the researchers report.
Human Immunodeficiency Virus
Image: NIAID
Previous studies have examined the interaction of viral evolution with the human immune system in single patients, finding that people with certain variants of human leukocyte antigen (HLA), a key recognition element in the human immune system, can better control the infection. Those studies provided "a small window of what's going on," said Colm O'hUigin, who studies viral evolution at the National Cancer Institute in Frederick, Md., and was not involved in the research. "This take is different because it gave a longer-term [view]-- and that is that the HLA is beginning to shape the virus in the population." The study examined the interaction of different HLA variants with the virus in nine cohorts of patients from around the world, totaling 2875 subjects. The researchers initially focused on HLA-B51, which is known to mitigate a patient's infection; in patients who carry it, however, the virus often develops an "escape mutation" which can get around HLA-B51's protective effects. The researchers found the escape mutation in 96% of people infected with HIV who have HLA-B51. But in regions where HLAB51 was common, the escape mutation was common too, showing that the virus was evolving to circumvent the immune system. Examination of 13 other escape mutations showed the same pattern. For example, explained study author linkurl:Bruce Walker,;http://www.hhmi.org/research/investigators/walkerbd_bio.html director of the Ragon Institute for HIV research at Harvard, the Massachusetts Institute of Technology, and the Massachusetts General Hospital, HLA B51 is quite common in Japan. Correspondingly, the viral mutation related to HLA-B51 is also much more prevalent in infected people -- not just in those who are B51-positive, but in those who are B51-negative as well. "It basically becomes the dominant population virus," Walker said. Since the virus can develop strategies to evade the human immune system, it is likely capable of doing the same to any vaccine. Consequently, said O'hUigin, a vaccine designed against viral epitopes that HLA recognizes "will be initially successful, perhaps, but the virus itself will adapt to the vaccination strategy and will begin to persist in forms that are evasive to the vaccine." Walker stressed that the findings may not be as dire as they appear. "At first glance, you look at this and think, oh my God, this is bad," he said. "On the other hand, as the virus changes, this may expose other targets" for vaccines. Also, he noted, some regions of the virus mutate less, and if they do mutate, the virus becomes weaker, so it may be possible to identify and target those areas instead. Overall, Walker said, the study underscores the necessity of tracking HIV not just in the US, but in populations worldwide. "It helps to explain why HIV is different in different parts of the world -- because it has to adapt to different parts of the world."
**__Related stories:__***linkurl:The secret of HIV control;http://www.the-scientist.com/blog/display/55259/
[4th December 2008]*linkurl:HIV's time of origin confirmed;http://www.the-scientist.com/blog/display/55064/
[1st October 2008]*linkurl:5 HIV Treatment Strategies;http://www.the-scientist.com/article/display/53516/
[September 2008]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies